Increased radiation with SABR boost seems to enhance local control but with reduced overall survival at highest dose
However, few individuals with newly diagnosed lung cancer engage in daily moderate-to-vigorous physical activity
Complication rates substantially higher after abnormal findings with low-dose CT lung cancer screening versus those seen in National Lung Screening Trial
Survival similar among racial and ethnic groups; ECOG performance status linked to survival
10-year lung cancer-specific survival of 80 percent reported in 2006 persisted, with 81 percent survival at 20 years
Greater incidence of grade 3 or higher adverse events from any cause seen in combination group versus monotherapy
Improvement in overall survival seen for patients receiving cisplatin or carboplatin with pemetrexed
26.6 percent of people alive five years after a lung cancer diagnosis, with 22 percent improvement seen over last five years
Updated guidelines recommend annual screening for those aged 50 to 80 years who currently smoke, or formerly smoked
Female-to-male incidence rate ratio increased from 0.73 during 2000 to 2004 to 1.05 during 2015 to 2019